Novavax (NVAX, $3.18, $0.59, 22.78%) shares gained after the company said its virus-like particle vaccine triggered a "robust immune response" and provided protection against the H9N2 strain of avian influenza in a pre-clinical study.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.